Infective meningitis

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1921 times

38 Infective meningitis

Key points

The brain and spinal cord are surrounded by three membranes, which from the outside inwards are the dura mater, the arachnoid mater and the pia mater. Between the arachnoid mater and the pia mater, in the subarachnoid space, is found the cerebrospinal fluid (CSF) (Fig. 38.1). This fluid, of which there is ∼︀150 mL–1 in a normal individual, is secreted by the choroid plexuses and vascular structures which are in the third, fourth and lateral ventricles. CSF passes from the ventricles via communicating apertures to the subarachnoid space, after which it flows over the surface of the brain and the spinal cord (see Fig. 38.1). The amount of CSF is controlled by resorption into the bloodstream by vascular structures in the subarachnoid space, called the arachnoid villi. Infective meningitis is an inflammation of the arachnoid and pia mater associated with the presence of bacteria, viruses, fungi or protozoa in the CSF. Meningitis is one of the most emotive of infectious diseases, and for good reason: even today, infective meningitis is associated with significant mortality and risk of serious sequelae in survivors.

Aetiology and epidemiology

In the UK, around 1500 cases of meningitis are notified annually. However, this almost certainly under represents the true incidence of meningitis. Viruses are the most common cause of meningitis, and are often less serious than bacterial or fungal forms of the disease.

Bacterial meningitis

Although bacterial meningitis occurs in all age groups, it is predominantly a disease of young children, with 40–50% of all cases occurring in the first 4 years of life. Two bacteria, N. meningitidis and S. pneumoniae, account for about 75% of cases. However, the pattern of micro-organisms causing meningitis is related to the age of the patient and the presence of underlying disease.

N. meningitidis is the most common cause of bacterial meningitis from infancy through to middle age, with peaks of incidence in the under-5-year age group and in adolescents. There are several serogroups of N. meningitidis, including A, B, C, W135 and Y. In the late twentieth century, serogroups B and C accounted for 60–65% and 35–40% of infections in the UK, respectively. However, with the introduction of vaccination against N. meningitidis serogroup C (MenC) into the routine immunisation programme in 1999, serogroup B now accounts for well over 80% of all meningococcal disease. There is currently no vaccine available for N. meningitidis serogroup B. Serogroups A and W135 predominate in Africa and the Middle East. A quadrivalent vaccine against serogroups A, C, W135 and Y is available to protect travellers to countries of risk. S. pneumoniae is the most common cause of meningitis in adults aged over 45 years, but almost half of all cases of pneumococcal meningitis occur in children aged under 5 years. It has a poorer outcome than meningococcal meningitis. Vaccination against the most common serotypes of S. pneumoniae using a conjugate vaccine was added to the routine childhood immunisation programme in the UK in 2006: the original 7-valent vaccine was then replaced by a 13-valent vaccine in Spring 2010. A different 23-valent polysaccharide vaccine is available for certain patient groups at risk of pneumococcal infection.

Haemophilus influenzae type b (Hib) was once the major cause of bacterial meningitis in children aged 3 months to 5 years, but introduction of routine immunisation in 1992 has almost eliminated Hib disease in the UK and other developed countries.

Although patients with meningococcal or Hib meningitis are potentially infectious, most cases of meningitis due to these bacteria are acquired from individuals who are asymptomatic nasopharyngeal carriers. People living in the same household as a patient with meningococcal disease have a 500–1200-fold increased risk of developing infection if they do not receive chemoprophylaxis (see later). Susceptible young children who are household contacts of a case of Hib disease have a similarly increased risk of becoming infected. Epidemics of meningococcal disease sometimes occur. In developed countries, these take the form of clusters of cases among people living in close proximity (e.g. in schools or army camps) or in a particular geographical area. In Africa, large epidemics with many thousands of cases occur, usually during the dry season.

In the neonatal period, group B streptococci are the most common cause of bacterial meningitis. Other causes of neonatal meningitis include Escherichia coli and other Enterobacteriaceae, Listeria monocytogenes, Staphylococcus aureus and enterococci. In most cases, infection is acquired from the maternal genital tract around the time of delivery, but transmission between patients can also occur in hospitals.

L. monocytogenes is also an occasional cause of meningitis in immunocompromised patients. Meningitis can also occur as a complication of neurosurgery, especially in patients who have ventriculoatrial or ventriculoperitoneal shunts. Coagulase-negative staphylococci are the major causes of shunt-associated meningitis, but other bacteria are important, including Enterobacteriaceae and S. aureus. Meningitis due to S. aureus may also be secondary to trauma, or local or haematogenous spread from another infective focus. Meningitis may also be a feature of multisystem bacterial diseases such as syphilis, leptospirosis and Lyme disease.

The decline in the incidence of tuberculous meningitis in developed countries has mirrored the fall in the incidence of tuberculosis in these countries. Tuberculous meningitis may occur as part of the primary infection or as a result of recrudescence of a previous infection.

Pathophysiology

Most cases of bacterial meningitis are preceded by nasopharyngeal colonisation by the causative organism. In most colonised individuals, infection will progress no further, but in susceptible individuals the organism invades the submucosa by circumventing host defences (e.g. physical barriers, local immunity, phagocytes) and gains access to the CNS by invasion of the bloodstream and subsequent haematogenous seeding of the CNS. Other less common routes by which micro-organisms can reach the meninges include:

Once in the subarachnoid space, the infection spreads widely and incites a cascade of meningeal inflammation. The cerebral tissue is not usually directly involved although cerebral abscess may complicate some types of meningitis.

The micro-organisms that most frequently cause meningitis are capable of doing so because they have a variety of virulence factors, including mechanisms for:

Overall, the net result of infection is vascular endothelial injury and increased blood–brain barrier permeability leading to the entry of many blood components into the subarachnoid space. This contributes to cerebral oedema and elevated CSF protein levels. In response to the cytokine response, neutrophils migrate from the bloodstream into the CSF. Cerebral oedema contributes to intracranial hypertension and a consequent decrease in cerebral blood flow. Anaerobic metabolism ensues, which contributes to increased lactate and decreases glucose concentrations. If this uncontrolled process is not modulated by effective treatment, transient neuronal dysfunction or permanent neuronal injury results.

Diagnosis

The definitive diagnosis of meningitis is established by detection of the causative organism and/or demonstration of biochemical changes and a cellular response in CSF. CSF is obtained by lumbar puncture, where a needle is inserted between the posterior space of the third and fourth lumbar vertebrae into the subarachnoid space. Before performing lumbar puncture, the possibility of precipitating or aggravating existing brain herniation in patients with intracranial hypertension must be considered. A CT scan should be performed before undertaking lumbar puncture if any neurological abnormalities are present.

In health, the CSF is a clear colourless fluid which, in the lumbar region of the spinal cord, is at a pressure of 50–150 mmH2O. There may be up to 5 cells/μL, the protein concentration is up to 0.4 g/L and the glucose concentration is at least 60% of the blood glucose (usually 2.2–4.4 mmol/L). Table 38.1 shows how the cell count and biochemical measurements can be helpful in determining the type of organism causing meningitis.

In bacterial and fungal meningitis, organisms may be visible in Gram-stained smears of the CSF. The common causes of bacterial meningitis are easily distinguished from each other by their Gram stain appearance. Special stains, such as the Ziehl–Neelsen method, are necessary to visualise mycobacteria. However, only small numbers of mycobacteria are present in the CSF in tuberculous meningitis and direct microscopy is often unrevealing. Although cryptococci can be visualised by Gram staining, they are often more easily seen with India ink staining, which highlights their prominent capsules.

Regardless of the microscopic findings, CSF should be cultured to try to confirm the identity of the causative organism and to facilitate further investigations such as antibiotic sensitivity testing and typing. Special cultural techniques are required for mycobacteria, fungi and viruses. Cultures of other sites are sometimes helpful. In suspected bacterial meningitis, blood for culture should always be obtained. Bacteraemia occurs in only 10% of patients with meningococcal meningitis but is more common in most other forms of meningitis. In suspected meningococcal disease, culture of a nasopharyngeal swab may be helpful because antibiotic penetration at this site is less. It increases the chances of isolating meningococci when antibiotics were administered to the patient before presentation to hospital.

Non-culture-based methods are increasingly used to investigate the aetiology of meningitis. In particular, molecular amplification techniques such as polymerase chain reaction (PCR) are now widely used to detect meningococci, pneumococci, Mycobacterium tuberculosis and various viruses, including herpes simplex viruses and enteroviruses.

Serum antibodies to N. meningitidis and various viruses may be detected, but these investigations usually depend on demonstration of seroconversion between two samples collected a week or more apart, and are therefore undertaken more for public health than clinical reasons. Patients with tuberculous meningitis may have a positive Mantoux test or an interferon-gamma release assay.

Drug treatment

Acute bacterial meningitis is a medical emergency that requires urgent administration of antibiotics. Other considerations in some forms of meningitis include the use of adjunctive therapy such as steroids, and the administration of antibiotics to prevent secondary cases.

Antimicrobial therapy

Recommended regimens

Clinical urgency determines that empirical antimicrobial therapy will usually have to be prescribed before the identity of the causative organism or its antibiotic sensitivities are known. Consideration of the epidemiological features of the case, together with microscopic examination of the CSF, is often helpful in identifying the likely pathogen. However, empiric therapy is usually with broad-spectrum antimicrobial therapy to cover all likely pathogens, at least until definitive microbiological information is available. For the purpose of selecting empiric antimicrobial therapy, patients with acute bacterial meningitis can be categorised into four broad groups: neonates and infants aged below 3 months; immunocompetent older infants, children and adults; immunocompromised patients; and those with ventricular shunts.

Antibiotics for meningitis in neonates and infants aged below 3 months

The most important pathogens in neonates include group B streptococci, E. coli and other Enterobacteriaceae, L. monocytogenes. In many centres, a third-generation cephalosporin such as cefotaxime or ceftazidime, along with amoxicillin or ampicillin, is the empiric therapy of choice for neonatal meningitis (Galiza and Heath, 2009). Cephalosporins penetrate into CSF better than aminoglycosides, and their use in Gram-negative bacillary meningitis has contributed to a reduction in mortality to less than 10%. Other centres continue to use an aminoglycoside, such as gentamicin, together with benzylpenicillin, ampicillin or amoxicillin as empiric therapy. This approach remains appropriate, especially in countries such as the UK where group B streptococci are by far the predominant cause of early-onset neonatal meningitis. Whichever empiric regimen is used, therapy can be altered as appropriate once the pathogen has been identified. Suitable dosages are shown in Table 38.2.

Table 38.2 Suitable antibiotic regimens for treatment of acute bacterial meningitis in different age groups

Age group First-choice antibiotic therapy Alternative therapies
Neonates, aged <8 days Ampicillin, 50 mg/kg twice daily or amoxicillin 25 mg/kg twice daily and cefotaxime 50 mg/kg twice daily or ceftazidime 50 mg/kg twice daily Benzylpenicillin 50 mg twice daily and ampicillin 50 mg/kg twice daily or amoxicillin 25 mg/kg twice daily and gentamicin 2.5 mg/kg twice daily
Neonates, aged 8–28 days Ampicillin 50 mg/kg four times daily or amoxicillin 25 mg/kg three times daily and cefotaxime 50 mg/kg three times daily or ceftazidime 50 mg/kg three times daily Benzylpencillin 50 mg three or four times daily or ampicillin 50 mg/kg three or four times daily or amoxicillin 25 mg/kg three times daily and gentamicin 2.5 mg/kg three times daily
Infants, aged 1–3 months Ampicillin 50 mg/kg four times daily or amoxicillin 25 mg/kg three times daily and cefotaxime 50 mg/kg three times daily or ceftriaxone 75–100 mg/kg once daily  
Infants and children aged >3 monthsa Cefotaxime 50 mg/kg three times daily or ceftriaxoneb 75–100 mg/kg once daily Ampicillin 50 mg/kg four times daily or amoxicillin 25 mg/kg three times daily or benzylpenicillinc 30 mg/kg 4-hourly and chloramphenicold 12.5–25 mg/kg four times daily
Adults Cefotaximee 2 g three times daily or ceftriaxoneb,e 2–4 g once daily Benzylpenicillin 2.4 g 4-hourly or ampicillin 2–3 g four times daily or amoxicillin 2 g three or four times daily and chloramphenicold 12.5–25 mg/kg four times daily

a Calculated doses for children should not exceed maximum recommended doses for adults.

b Ceftriaxone should not be administered to neonates within 48 h of completion of infusions of calcium-containing solutions; caution should be exercised in older age groups.

c Benzylpenicillin is inactive against H. influenzae and should therefore not be used in children aged <5 years.

d Monitoring of serum chloramphenicol levels is recommended, especially in children aged 4 years.

e Add ampicillin or amoxicillin to cover L. monocytogenes in elderly patients or where Gram-positive bacilli seen in CSF.

In infants outside the immediate neonatal period, the classic neonatal pathogens account for a decreasing number of cases of meningitis and the common bacteria of meningitis in childhood (see later) become increasingly important. Amoxicillin or ampicillin plus cefotaxime or ceftriaxone is the recommended treatment. Therapy with amoxicillin or ampicillin and gentamicin is unsuitable for this age group because it provides inadequate cover against H. influenzae.

Antibiotics for meningitis in older infants, children and adults

Antimicrobial therapy has to cover S. pneumoniae, N. meningitidis and, in children aged below 5 years, H. influenzae (Yogev and Guzman-Cottrill, 2005). Achievable antibiotic CSF concentrations are compared with the susceptibilities of the common agents of meningitis in Table 38.3. Third-generation cephalosporins, such as cefotaxime, are now widely used in place of the traditional agents of choice, chloramphenicol, ampicillin, amoxicillin and penicillin (see Table 38.2). This change has stemmed from concern over the rare but potentially serious adverse effects of chloramphenicol and the emergence of resistance to penicillin, ampicillin and chloramphenicol among S. pneumoniae and H. influenzae in particular. Chloramphenicol resistance and reduced susceptibility to penicillin have also been reported in N. meningitidis. The third-generation cephalosporins have a broad spectrum of activity that encompasses not only the three classic causes of bacterial meningitis but also many other bacteria that are infrequent causes of meningitis. However, cephalosporins are inactive against L. monocytogenes, and amoxicillin or ampicillin should be added where it is possible that the patient may have listeriosis, for example in elderly patients, or where Gram-positive bacilli are seen on Gram stain. Although earlier-generation cephalosporins such as cefuroxime achieve reasonable CSF penetration and are active against the agents of meningitis in vitro, they do not effectively sterilise the CSF and should not be used to treat meningitis.

Ceftriaxone is a third-generation cephalosporin with a spectrum of activity comparable to that of cefotaxime. However, because of the potential for calcium chelation in vivo, ceftriaxone must not be administered within 48 h of the completion of infusions of calcium-containing solutions in neonates. The risk of precipitation is much lower in patients >28 days of age. Nevertheless, caution should still be exercised when treating older age groups, especially in the early treatment of meningococcal infections (where calcium-containing products are commonly used for resuscitation).

In meningitis due to N. meningitidis and H. influenzae, prompt administration of chemoprophylaxis to eliminate nasopharyngeal carriage can reduce the risk of secondary cases in close contacts of the case.

S. pneumoniae

Benzylpenicillin was once widely regarded as the treatment of choice for pneumococcal meningitis. However, pneumococci resistant to penicillin have emerged across the world, presenting a major therapeutic challenge in view of the severity of pneumococcal meningitis.

Although currently only about 5% of pneumococci in the UK are penicillin resistant, the frequency of resistance is increasing, and resistance rates of more than 50% have been reported in other countries, including Spain, Hungary and South Africa. Penicillin resistance in pneumococci is defined in terms of the minimum inhibitory concentration (MIC) of penicillin. Most strains have a MIC value of 0.1–2.0 mg/L and are defined as having moderate resistance; strains with an MIC value of more than 2 mg/L are considered highly resistant. This distinction is relevant for less serious infections with moderately resistant strains, which may still respond to adequate doses of some β-lactam antibiotics, such as cefotaxime, ceftriaxone or a carbapenem. However, the clinical outcome of meningitis with penicillin-resistant pneumococci treated with a β-lactam antibiotic as monotherapy is less good. For this reason, many guidelines, including those produced by the Infectious Diseases Society of America, now recommend therapy with a combination of a third-generation cephalosporin and vancomycin (McIntosh, 2005). This approach has not been adopted universally in the UK but should certainly be considered for patients who might have acquired their infection in a location where the incidence of penicillin resistance is high. Where vancomycin is given intravenously to treat meningitis, it is important to aim for trough serum levels of 15–20 mg/L because of the limited CSF penetration of vancomycin. Another problem is the emergence of pneumococci that are tolerant to vancomycin, that is, they are able to survive, but not proliferate, in the presence of vancomycin. Although such strains are uncommon, the outcome of meningitis treated with vancomycin is poor (Cottagnoud and Tauber, 2004).

Other antibiotics may be useful in treating pneumococcal meningitis. Use of rifampicin in combination with a cephalosporin and/or vancomycin is sometimes recommended, but there are few data confirming this can improve the response rate in either penicillin-sensitive or -resistant pneumococcal meningitis. The dose of rifampicin is 600 mg twice daily in adults or 10 mg/kg (maximum 600 mg) twice daily in children. Chloramphenicol is a suitable alternative to penicillin for treatment of meningitis due to penicillin-sensitive strains, for example in patients who are penicillin allergic. However, chloramphenicol is not recommended for treating penicillin-resistant pneumococcal meningitis: although isolates may appear sensitive to chloramphenicol on routine laboratory testing, bactericidal activity is often absent and the clinical response is usually poor.

Consideration of alternative antibiotics for treatment of penicillin-resistant pneumococcal meningitis is largely based on case reports rather than clinical trials. Success has been reported with meropenem as monotherapy, and in conjunction with rifampicin. Moxifloxacin is a new-generation quinolone antibiotic with enhanced activity against Gram-positive bacteria, including S. pneumoniae, which has shown promise in experimental pneumococcal meningitis. Linezolid has excellent CSF penetration but does not have bactericidal activity, and clinical experience in treating meningitis has been variable (Rupprecht and Pfister, 2005).

Daptomycin is an interesting option that has potent bactericidal activity against penicillin-sensitive and -resistant pneumococci, but without being bacteriolytic. This may be an advantage in that bacterial intracellular components that contribute to the inflammatory response are not liberated by bacterial killing. Indeed, in treating experimental pneumococcal meningitis, daptomycin gives a better clinical outcome than conventional treatment.

The unpredictable nature of the response to therapy of penicillin-resistant pneumococcal meningitis means that patients require close observation during treatment, for example monitoring of C-reactive protein (CRP). Repeat examination of CSF during therapy should also be considered.

Chemoprophylaxis against meningococccal and Hib infection

In meningococcal meningitis, spread between family members and other close contacts is well recognised; these individuals should receive chemoprophylaxis as soon as possible, preferably within 24 h. Sometimes, chemoprophylaxis may be indicated for other contacts, but the decision to offer prophylaxis beyond household contacts should only be made after obtaining expert advice (Box 38.1). Of the antibiotics conventionally used to treat meningococcal infections, only ceftriaxone reliably eliminates nasopharyngeal carriage; where another antibiotic has been used for treatment, the index case also requires chemoprophylaxis. A number of antibiotics are suitable as prophylaxis (Box 38.2).

Box 38.1 Indications for chemoprophylaxis in contacts of cases of infection with N. meningitidis or H. influenzae type b

Box 38.2 Recommended prophylactic regimens for contacts of cases of infection with N. meningitidis or H. influenzae type b

Meningococcal infection
Ciprofloxacina (oral)  
Children aged 1 month – 4 years
Children aged 5–12 years
Adults
125 mg as a single dose
250 mg as a single dose
500 mg as a single dose
Rifampicin (oral)  
Children aged <1 year 5 mg/kg twice daily on 2 consecutive days
Children aged 1–12 years 10 mg/kg (max 600 mg) twice daily on 2 consecutive days
Adults 600 mg twice daily on 2 consecutive days
Azithromycina (oral)Pregnant women 500 mg as a single dose
Ceftriaxonea (intramuscular)  
Children aged <12 years
Adults
125 mg as a single dose
250 mg as a single dose
Invasive Haemophilus influenzae type b infection
Rifampicin (oral)  
Children aged 1–3 months 10 mg/kg once daily for 4 days
Children aged >3 months 20 mg/kg once daily (max 600 mg) for 4 days
Adultsb 600 mg once daily for 4 days

a Not licensed for this indication.

b For pregnant women, obtain expert advice.

Ciprofloxacin is now widely recommended for contacts of all ages (including pregnant and breast-feeding women) because of the convenience of single-dose administration and, unlike rifampicin, it does not interact with oral contraceptives and is readily available in community pharmacies. Although anaphylactoid reactions have been reported to occur in individuals receiving ciprofloxacin as chemoprophylaxis, none of these reactions has been fatal. If the strain is confirmed as group C (or A, W135 or Y), vaccination is normally offered to contacts who were given prophylaxis. There is no need to vaccinate the patient. There is currently no vaccine that protects against group B disease, which accounts for about 70% of cases of meningococcal disease in Europe.

Chemoprophylaxis against Hib infection is usually only indicated where there is an unimmunised child in the vulnerable age group in the household (see Box 38.1). Only rifampicin has been proved to be effective in eliminating nasopharyngeal carriage (see Box 38.2). Unimmunised household contacts aged below 4 years should also receive Hib vaccine. The index case should also receive rifampicin in order to eliminate nasopharyngeal carriage, and should be immunised, irrespective of age.

Antibiotics for meningitis in special groups

Tuberculous meningitis

The outcome in tuberculous meningitis relates directly to the severity of the patient’s clinical condition on commencement of therapy. A satisfactory response demands a high degree of clinical suspicion such that appropriate chemotherapy is initiated early, even if tubercle bacilli are not demonstrated on initial microscopy. Most currently used antituberculous agents achieve effective concentrations in the CSF in tuberculous meningitis. Detailed discussion of antituberculous therapy is given in Chapter 40. Adjunctive steroid therapy is of value in patients with more severe disease, particularly those who suddenly develop cerebral oedema soon after starting treatment or who appear to be developing a spinal block. However, routine use of steroids is not recommended. They may suppress informative changes in the CSF and interfere with antibiotic penetration by restoring the blood–brain barrier. Early neurosurgical management of hydrocephalus by means of a ventriculoperitoneal or ventriculoatrial shunt is also important in improving the prospects for neurological recovery.

Cryptococcal meningitis

The standard treatment of cryptococcal meningitis is amphotericin B, given intravenously at a dose of 0.7–1.0 mg/kg/day, with or without flucytosine 100 mg/kg/day, for 6–10 weeks. Addition of flucytosine results in quicker clearance of yeasts from the CSF, although it is debatable whether this results in improved clinical outcome. Lipid formulations of amphotericin B, such as liposomal amphotericin B, at doses of 4–6 mg/kg/day have comparable efficacy to, and fewer side effects than, conventional amphotericin B at a dose of 0.7 mg/kg. As an alternative to prolonged therapy with two potentially toxic drugs, 2 weeks therapy with amphotericin B and flucytosine may be given, followed by consolidation therapy with fluconazole 400 mg/day for at least 10 weeks. Initial treatment with fluconazole 400–800 mg/day plus flucytosine is clinically inferior to amphotericin B-based regimens, and in any case is no better tolerated than amphotericin B-based regimens. Regular haematological and biochemical monitoring is recommended during treatment, along with measurement of serum concentrations of flucytosine (which should not exceed 80 mg/L).

The clinical response to treatment of cryptococcal meningitis is slow, and it often takes 2 or 3 weeks to sterilise the CSF. Monitoring of intracranial pressure is essential, with large-volume CSF drainage indicated if the opening pressure reaches 250 mmHg. Serial CSF cultures are occasionally helpful in following the response to treatment, but monitoring of cryptococcal antigen titres in serum or CSF is of little value.

Patients with HIV infection treated for cryptococcal meningitis should then receive fluconazole indefinitely, or at least until immune reconstitution occurs. The dose of fluconazole may be reduced to 200 mg/day, depending on the patient’s clinical condition (Bicanic and Harrison, 2004). Itraconazole offers less good CSF penetration than fluconazole, but is a suitable alternative as maintenance therapy at a dose of 200–400 mg/day for patients unable to tolerate fluconazole. Clinical data with newer triazoles such as voriconazole and posaconazole remain limited, but these agents may be useful, especially in the rare situation of fluconazole-resistant cryptococcal meningitis. The echinocandin class of antifungals does not possess useful activity against Cryptococcus.

Viral meningitis

None of the currently available antiviral agents has useful activity against human enteroviruses, the commonest causes of viral meningitis (Big et al., 2009). Fortunately, however, the condition is usually self-limiting. The viruses that commonly cause this condition, herpes simplex and varicella zoster meningoencephalitis, are treated with high-dose aciclovir, 10 mg/kg three times daily for at least 10 days (adults and children aged 12 years and over). For younger children, the recommended doses are 20 mg/kg three times daily for infants up to age 3 months, and 500 mg/m2 three times daily for those aged 3 months to 12 years.

Steroids as adjunctive therapy in bacterial meningitis

In pharmacological doses, corticosteroids, and in particular dexamethasone, regulate many components of the inflammatory response and also lower CSF hydrostatic pressure. However, by reducing inflammation and restoring the blood–brain barrier, they may reduce CSF penetration of antibiotics. The benefits of steroids in the initial management of meningitis due to M. tuberculosis and Hib are well established, although in other forms of bacterial meningitis the evidence has been less compelling. Methodological flaws have been identified in older studies where no benefit was seen from use of adjunctive steroid therapy. Recent work has found that adjunctive dexamethasone therapy reduces the rate of unfavourable outcomes from 25% to 15% in adults with bacterial meningitis. In this series, adjunctive treatment with dexamethasone was given before or with the first dose of antibiotics, without serious adverse effects. Overall, corticosteroids significantly reduce rates of mortality, severe hearing loss and neurological sequelae. The use of adjunctive dexamethasone is now recommended for children and adults with community-acquired bacterial meningitis, regardless of bacterial aetiology (Brouwer et al., 2010). Adjunctive therapy should be initiated before or with the first dose of antibiotics and continued for 4 days. The recommended dose for adults is 10 mg four times daily for 4 days (children 0.15 mg/kg four times daily for 4 days).

Intrathecal and intraventricular administration of antibiotics

Intrathecal administration, that is, administration into the lumbar subarachnoid space, of antibiotics was once widely used to supplement levels attained by concomitant systemic therapy. However, there is little evidence for the efficacy of this route of delivery, and it is now rarely used. In particular, it produces only low concentrations of antibiotic in the ventricles and therefore does little to prevent ventriculitis, one of the most serious complications of meningitis. Direct intraventricular administration of antibiotics in meningitis is important in certain types of meningitis, especially where it is necessary to use an agent, for example vancomycin or an aminoglycoside, that penetrates CSF poorly (Shah et al., 2004). The most common situation is in shunt-associated meningitis, where multiple antibiotic-resistant coagulase-negative staphylococci are the major pathogens, and where conveniently the patient will often have an external ventricular drain through which antibiotics can be administered.

There are considerable differences in recommended doses of antibiotics for intrathecal or intraventricular administration. A dose of 15–20 mg vancomycin per day is recommended for treatment of shunt-associated meningitis in adults with an extraventricular drain, and 10 mg/day for neonates and children. The paediatric dose may need to be reduced to 5 mg/day if ventricular size is reduced, or increased to 15–20 mg/day if the ventricular size is increased. In all patients, the dose frequency should be decreased to once every 2–3 days if CSF is not draining freely. The CSF vancomycin concentration should be measured after 3–4 days, aiming for a trough concentration of <10 mg/L. Recommended doses of antibiotics are otherwise largely based on anecdotal experience (Table 38.5).

Patient care

Common problems in the treatment of meningitis are set out in Table 38.6.

Prevention of person-to-person transmission

Patients with meningitis may be infectious to others. Neonates with meningitis usually have generalised infections, and the causative organisms can often be isolated from body fluids and faeces. Babies with meningitis should therefore be isolated to prevent infection spreading to other patients. Patients with meningococcal or Hib meningitis should be isolated until after at least 48 h of antibiotic therapy. Contacts of these patients may be asymptomatic carriers and potentially infectious to others and/or at risk of developing invasive infection themselves. Chemoprophylaxis and vaccination can reduce these risks (see earlier). Patients with most other types of meningitis do not represent a significant infectious hazard, and enhanced infection control precautions are not usually necessary.

Case studies

References

Arnell K., Enblad P., Wester T., et al. Treatment of cerebrospinal fluid shunt infections in children using systemic and intraventricular antibiotic therapy in combination with externalization of the ventricular catheter: efficacy in 34 consecutively treated infections. J. Neurosurg.. 2007;107:213-219.

Bicanic T., Harrison T.S. Cryptococcal meningitis. Br. Med. Bull.. 2004;72:99-118.

Big C., Reineck L.A., Aronoff D.M. Viral infections of the central nervous system: a case-based review. Clin. Med. Res.. 2009;7:142-146.

Brouwer M.C., McIntyre P., de Gans J., et al. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews.. 2010. Issue 9. Art No. CD004405

Cottagnoud P.H., Tauber M.G. New therapies for pneumococcal meningitis. Expert Opin. Investig. Drugs. 2004;13:393-401.

Galiza E.P., Heath P.T. Improving the outcome of neonatal meningitis. Curr. Opin. Infect. Dis.. 2009;22:229-234.

Health Protection Agency Meningococcus and Haemophilus Forum. Guidance for Public Health Management of Meningococcal Disease in the UK, updated January. Health Protection Agency. 2011.

Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Br. J. Neurosurg.. 2000;14:7-12.

McIntosh E.D. Treatment and prevention strategies to combat pediatric pneumococcal meningitis. Expert Rev. Anti-Infect. Ther.. 2005;3:739-750.

Ross J.S., Wilson K.J.W. Foundations of Anatomy and Physiology, fifth ed., Edinburgh: Churchill Livingstone; 1981:172-173.

Rupprecht T.A., Pfister H.W. Clinical experience with linezolid for the treatment of central nervous system infections. Eur. J. Neurol.. 2005;12:536-542.

Shah S.S., Ohlsson A., Shah V.S. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database of Systematic Reviews. 2004. Issue 4. Art. No. CD004496. doi:10.1002/14651858.CD004496.pub2. Available at http://www2.cochrane.org/reviews/en/ab004496.html Accessed 20 April 2011

Yogev R., Guzman-Cottrill J. Bacterial meningitis in children: critical review of current concepts. Drugs. 2005;65:1097-1112.